Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resveratrol - Sirtris

Drug Profile

Resveratrol - Sirtris

Alternative Names: 184072; GSK184072; SRT 501

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirtris Pharmaceuticals
  • Developer GlaxoSmithKline; Sirtris
  • Class Antidementias; Antineoplastics; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Antioxidants; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - MELAS syndrome

Highest Development Phases

  • Discontinued Cancer metastases; Colorectal cancer; MELAS syndrome; Multiple myeloma; Multiple sclerosis; Optic neuritis; Type 2 diabetes mellitus

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in Denmark (PO)
  • 02 Dec 2010 Discontinued - Phase-II for Multiple myeloma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top